influenza
viru
envelop
viru
belong
orthomixovirida
peculiar
viru
segment
singlestrand
negativesens
rna
genom
enhanc
potenti
recombin
three
type
influenza
viru
b
c
far
recogn
influenza
viru
type
b
associ
season
epidem
influenza
viru
type
occasion
give
rise
worldwid
pandem
three
ha
antigen
two
na
antigen
influenza
virus
caus
widespread
diseas
sustain
humantohuman
transmiss
bird
differ
ha
antigen
na
antigen
current
known
minor
antigen
variant
aris
yearli
within
specif
subtyp
season
epidem
influenza
b
virus
also
undergo
antigen
drift
signific
part
annual
influenza
burden
caus
two
cocircul
antigen
distinct
lineag
call
yamagata
victoria
lineag
influenza
viru
type
b
show
similar
pathogen
potenti
human
cocircul
season
epidem
complex
mechan
basi
pandem
event
case
major
antigen
variant
influenza
antigen
shift
may
gener
genet
reassort
viru
strain
human
avian
origin
largest
reservoir
influenza
strain
host
mammal
suscept
infect
swine
virus
circul
differ
anim
speci
may
also
introduc
directli
human
popul
avian
influenza
virus
subtyp
also
associ
sporad
infect
human
level
herd
immun
human
new
reassort
virus
usual
low
make
possibl
rapid
spread
worldwid
pandem
underli
increas
virul
pandem
influenza
strain
influenza
viru
b
elimin
high
titer
respiratori
secret
spread
droplet
also
contact
contamin
hand
object
gener
assum
innat
adapt
immun
play
role
control
influenza
viru
infect
individu
level
particular
presenc
crossreact
memori
b
cell
respons
differ
suscept
influenza
viru
infect
diseas
sever
observ
young
peopl
adult
itali
data
collect
nationwid
activ
sentinel
surveil
network
influnet
show
among
clinic
swab
collect
season
test
posit
influenza
http
wwwtrovanormesalut
govitnormerendernormsanpdf
part
seri
incid
season
influenza
decreas
age
reach
minimum
valu
healthi
adult
correl
preexist
influenza
immun
influenza
infect
limit
upper
respiratori
tract
also
spread
lower
respiratori
tract
caus
respiratori
failur
addit
lung
failur
exacerb
bacteri
fungal
superinfect
debilit
individu
evalu
effect
influenza
vaccin
import
point
winterspr
season
number
respiratori
virus
cocircul
togeth
influenza
b
rhinoviru
metapneumoviru
respiratorysynciti
viru
enteroviru
coronaviru
adenoviru
itali
season
influenza
epidem
associ
annual
averag
excess
death
season
death
among
elderli
peopl
age
underli
cardiopulmonari
condit
chronic
diseas
influenza
infect
potenti
caus
addit
morbid
mortal
subject
immunocompromis
underli
diseas
therapi
fact
peopl
cancer
like
get
influenza
complic
upper
lower
respiratori
tract
infect
hospit
influenza
infect
three
five
time
higher
cancer
patient
gener
popul
mortal
rate
oncolog
patient
rel
risk
compar
gener
popul
consequ
health
author
recommend
vaccin
influenza
immunocompromis
host
close
contact
vaccin
also
import
prevent
intercurr
infect
may
requir
dose
reduct
delay
treatment
underli
malign
purpos
articl
highlight
impact
influenza
patient
cancer
capac
mount
protect
immunolog
respons
vaccin
thu
allow
italian
associ
medic
oncolog
aiom
make
suitabl
recommend
prevent
treatment
season
influenza
review
avail
data
present
literatur
includ
recommend
nation
health
author
impact
influenza
patient
cancer
capac
mount
protect
immunolog
respons
vaccin
data
avail
vaccin
strategi
improv
efficaci
influenza
vaccin
treatment
establish
infect
also
review
addit
expert
italian
societi
virolog
italian
health
author
list
among
author
provid
addit
biolog
clinic
epidemiolog
inform
greatli
help
clarifi
issu
absenc
clearcut
inform
literatur
result
avail
vaccin
potenti
sideeffect
two
type
influenza
vaccin
avail
inactiv
inject
vaccin
approv
use
subject
older
month
includ
healthi
peopl
pregnant
women
peopl
chronic
medic
condit
ii
live
attenu
influenza
vaccin
laiv
administ
nasal
spray
laiv
approv
use
healthi
peopl
year
age
pregnant
trival
inactiv
influenza
vaccin
may
includ
adjuv
enhanc
immunogen
usual
administ
singl
shot
immunocompet
individu
immunosuppress
subject
may
need
booster
administr
season
influenza
vaccin
contain
antigen
match
three
differ
influenza
strain
cocircul
season
epidem
influenza
b
due
constant
emerg
antigen
drift
variant
herd
immun
pressur
influenza
vaccin
need
yearli
updat
includ
escap
variant
detect
season
epidem
predict
circul
next
winterspr
season
updat
organ
network
sentinel
practition
refer
laboratori
influnet
virus
vaccin
close
match
circul
commun
vaccin
effect
greater
howev
even
virus
close
relat
vaccin
still
expect
provid
crossprotect
differ
relat
strain
influenza
virus
base
limit
crossprotect
two
influenza
b
lineag
inabl
accur
predict
influenza
b
lineag
circul
quadrival
influenza
vaccin
includ
influenza
b
strain
recent
approv
fda
european
medicin
agenc
pharmaceut
compani
like
transit
predominantli
produc
quadrival
vaccin
year
hundr
million
peopl
worldwid
receiv
season
influenza
vaccin
essenti
without
seriou
consequ
common
sideeffect
report
sore
red
tender
swell
inject
site
less
common
mild
arthromyalgia
lowgrad
fever
nausea
problem
occur
start
soon
vaccin
persist
day
rare
occas
influenza
vaccin
associ
seriou
complic
sever
allerg
reaction
inactiv
influenza
virus
cultur
chicken
egg
administr
influenza
vaccin
subject
allergi
chicken
egg
protein
avoid
influenza
vaccin
report
increas
risk
syndrom
gb
background
rate
mainli
base
experi
mass
immun
conduct
prevent
influenza
epidem
enhanc
surveil
gb
conduct
suggest
influenza
vaccin
public
health
benefit
albeit
associ
small
increas
risk
gb
success
immun
depend
intact
immun
system
produc
antibodi
tcell
respons
upon
antigen
exposur
patient
cancer
consid
function
immunosuppress
due
underli
diseas
andor
cancer
therapi
consequ
may
suboptim
serolog
respons
influenza
vaccin
although
antivir
prophylaxi
recent
use
prevent
influenza
viru
infect
specif
clinic
set
perivaccin
prophylaxi
postexposur
prophylaxi
famili
cluster
prophylaxi
well
season
prophylaxi
vaccin
effect
method
widespread
prevent
influenza
infect
inde
cdc
advisori
committe
immun
practic
acip
unit
state
recommend
season
influenza
vaccin
adult
without
contraind
diseaseor
medicationrel
immunosuppress
http
wwwcdcgovfluaboutdiseasehighriskhtm
howev
knowledg
serolog
respons
season
influenza
vaccin
remain
scanti
patient
cancer
particularli
spars
solid
tumor
tumor
heterogen
time
influenza
vaccin
rel
differ
chemotherapi
treatment
gener
lack
data
concern
vaccin
efficaci
influenza
infect
complic
make
difficult
compar
clinic
studi
far
report
literatur
result
eight
control
clinic
trial
look
efficaci
influenza
vaccin
pediatr
cancer
patient
review
children
receiv
chemotherapi
abl
gener
immun
respons
vaccin
albeit
weakli
healthi
children
children
asthma
children
cancer
complet
chemotherapi
month
vaccin
influenza
vaccin
safe
administ
report
persist
advers
reaction
studi
although
patient
receiv
chemotherapi
higher
incid
gener
malais
follow
vaccin
none
studi
report
clinic
outcom
seroprotect
antibodi
titer
seroconvers
least
fourfold
rise
hi
titer
achiev
patient
establish
diagnosi
lymphoprolif
disord
irrespect
previou
chemotherapi
administr
anoth
recent
review
metaanalysi
conduct
assess
influenza
vaccin
immunocompromis
patient
show
significantli
lower
incid
influenzalik
ill
vaccin
hiv
patient
cancer
patient
transplant
recipi
compar
placebo
vaccin
earli
studi
investig
serolog
respons
bival
inactiv
influenza
vaccin
patient
malign
protect
immun
two
influenza
strain
vaccin
achiev
patient
respect
studi
conduct
patient
lung
cancer
show
rate
respons
inactiv
trival
season
influenza
vaccin
similar
seen
healthi
subject
chemotherapi
within
previou
week
system
corticosteroid
medic
signific
effect
protect
hi
respons
howev
larg
trial
exist
replic
inform
data
regard
time
influenza
vaccin
regard
chemotherapi
administr
adult
solid
tumor
hematolog
malign
limit
three
studi
one
publish
two
recent
year
overal
patient
investig
studi
despit
pauciti
data
heterogen
patient
popul
suggest
tor
patient
solid
tumor
possibl
vaccin
given
midcycl
prefer
week
chemotherapi
andor
administr
subsequ
cycl
patient
hematolog
malign
highest
serolog
respons
appear
occur
follow
vaccin
administ
leukocyt
count
normal
initi
cycl
recent
publish
review
articl
polleya
et
al
recommend
vaccin
furthest
possibl
time
point
away
treatment
given
cycl
studi
mostli
conduct
children
compar
patient
complet
treatment
still
receiv
treatment
show
superior
respons
finish
treatment
studi
indic
gener
treat
cancer
patient
show
reduc
respons
influenza
vaccin
compar
healthi
subject
consider
number
cancer
patient
actual
reach
cutoff
level
seroprotect
unfortun
case
patient
treat
rituximab
impair
immun
respons
influenza
vaccin
report
associ
persist
memori
bcell
deplet
thu
context
rituximabinclud
therapi
altern
betterdefin
prophylactictherapeut
approach
need
limit
data
avail
efficaci
influenza
vaccin
patient
receiv
immunotherapi
biolog
agent
alon
combin
chemotherapi
vacanc
studi
show
biolog
agent
given
combin
cytotox
drug
seem
neg
affect
seroprotect
studi
patient
target
therapi
alon
especi
multikinas
inhibitor
better
immun
respons
treatment
group
latter
result
keep
recent
publish
report
show
singl
shot
influenza
vaccin
safe
effect
mount
antibodi
immun
respons
patient
treat
sunitinibor
sorafenib
immun
respons
compar
healthi
control
standard
influenza
vaccin
therefor
recommend
patient
cancer
patient
fragil
subject
influenza
vaccin
may
less
effect
due
impair
immun
system
reason
expos
laiv
trival
inactiv
vaccin
recommend
annual
influenza
prophylaxi
vaccin
influenza
reduc
sever
ill
complic
immunocompet
individu
data
demonstr
vaccin
effect
immunocompromis
individu
limit
among
hivposit
peopl
low
tcell
count
administr
inactiv
trival
vaccin
induc
protect
antibodi
titer
second
dose
vaccin
improv
immun
respons
lack
benefit
one
versu
two
dose
inactiv
influenza
trival
vaccin
also
document
patient
hematolog
tumor
recent
studi
demonstr
two
dose
adjuv
vaccin
requir
cancer
patient
undergo
chemotherapi
achiev
similar
seroprotect
rate
versu
achiev
control
given
one
dose
age
decreas
immun
respons
influenza
vaccin
adjuv
higher
dose
antigen
suppos
improv
immun
respons
better
protect
influenza
vacanc
studi
includ
cancer
patient
receiv
cytotox
andor
target
therapi
one
two
dose
vaccin
result
seroprotect
rate
respect
seroconvers
rate
respect
thu
two
dose
adjuv
vaccin
improv
immunoprotect
popul
suggest
potenti
detriment
effect
tumor
therapi
nonspecif
inflammatori
stimulu
due
adjuv
uniqu
immunolog
characterist
skin
dens
network
immunestimulatori
antigenpres
cell
togeth
progress
immun
techniqu
offer
possibl
way
improv
immunogen
low
respond
well
reduc
dosag
healthi
adult
studi
jo
et
al
show
intraderm
inject
onehalf
dose
trival
inactiv
split
vaccin
elicit
immun
respons
compar
elicit
full
dose
intramuscular
vaccin
among
cancer
patient
openlabel
studi
highdos
vaccin
versu
standard
dose
current
ongo
children
cancer
hiv
receiv
two
inject
either
dose
wwwclinicaltrialgov
vaccin
apart
protect
cancer
patient
could
increas
reduc
likelihood
infect
patient
isol
practic
feasibl
would
ethic
vaccin
household
contact
health
care
personnel
pivot
import
increas
level
herd
immun
local
environ
consequ
reduct
influenza
viru
circul
likelihood
infect
moreov
strict
prevent
measur
adopt
oncolog
ward
hospit
patient
develop
influenzalik
ill
even
result
viral
test
known
hygien
precaut
hand
wash
surgic
mask
etc
enforc
togeth
restrict
visitor
suspect
respiratori
ill
leukem
children
receiv
mainten
chemotherapi
last
year
report
suscept
viral
infect
probabl
due
higher
exposur
infect
peopl
school
daycar
contact
thu
appropri
therapi
togeth
continu
surveil
implement
prevent
practic
essenti
care
antivir
treatment
start
soon
suspicion
influenza
may
make
influenza
infect
milder
shorten
durat
ill
decreas
complic
popul
oseltamivir
zanamivir
target
neuraminidas
enzym
effect
treatment
influenza
infect
drug
typic
given
day
longer
durat
therapi
advoc
patient
undergo
chemotherapi
reduc
lymphocyt
count
prolong
viral
shed
may
occur
subject
sever
influenza
ie
influenza
pneumonia
ill
requir
iculevel
care
document
http
antivir
resist
oseltamivir
zanamivir
among
circul
influenza
virus
current
low
emerg
treatment
especi
protract
long
period
patient
cancer
develop
fever
influenzalik
ill
earli
antivir
therapi
given
empir
without
await
laboratori
confirm
hand
administr
antivir
drug
may
repres
feasibl
strategi
prevent
treatment
influenza
cancer
patient
may
benefit
prophylact
vaccin
eg
patient
receiv
rituximabinclud
therapi
emphas
influenza
vaccin
patient
cancer
safe
minim
invas
inexpens
aiom
recommend
vaccin
season
influenza
cancer
patient
without
contraind
untreat
tabl
recommend
statement
use
vaccin
season
influenza
patient
cancer
influenza
vaccin
patient
cancer
safe
minim
invas
inexpens
wide
util
patient
cancer
untreat
receiv
activ
therapi
includ
biolog
agent
solid
tumor
ideal
time
administ
vaccin
treatment
cycl
unclear
vaccin
household
contact
health
care
personnel
highli
recommend
bear
signific
implic
increas
level
herd
immun
microenviron
consequ
reduct
influenza
viru
circul
likelihood
infect
strict
prevent
measur
adopt
oncolog
ward
presenc
hospit
patient
develop
influenzalik
ill
trival
inactiv
vaccin
given
data
suggest
increas
seroprotect
rate
mean
vaccin
adjuv
higher
dose
antigen
second
dose
vaccin
quadrival
vaccin
recent
approv
unit
state
european
health
author
cancer
patient
treat
rituximabcontain
regimen
persist
perturb
bcell
compart
impair
immun
respons
influenza
vaccin
also
common
vaccin
thu
special
effort
need
improv
prevent
therapeut
strategi
refractori
patient
includ
prophylact
antivir
prospect
random
control
trial
better
defin
serolog
respons
clinic
benefit
influenza
vaccin
need
patient
popul
patient
patient
undergo
activ
treatment
phase
antineoplast
therapi
vaccin
vaccin
household
contact
health
care
personnel
also
recommend
welldesign
prospect
studi
need
identifi
optim
immunogen
strategi
season
influenza
vaccin
differ
clinic
condit
togeth
optim
time
vaccin
rel
chemotherapi
administr
summari
aiom
recommend
report
tabl
fund
partial
support
progetto
associazion
italiana
per
la
ricerca
sul
cancro
airc
